Affinage

ANXA1

Annexin A1 · UniProt P04083

Length
346 aa
Mass
38.7 kDa
Annotated
2026-06-09
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA1 (Annexin A1) is a calcium- and phospholipid-binding protein that serves as a central effector of glucocorticoid anti-inflammatory action and inflammation resolution, with broad additional roles in tumor signaling and tissue protection (PMID:12553880, PMID:19428336). In its canonical anti-inflammatory mode, ANXA1 is required for glucocorticoid-mediated suppression of eicosanoid generation, since cells lacking it overexpress COX-2 and PLA2 and resist dexamethasone (PMID:12553880); glucocorticoids drive this through PKCα/β phosphorylation of ANXA1 at Ser27, promoting plasma-membrane accumulation and externalization, a step opposed by PP2A (PMID:19428336). Externalized ANXA1 is cleaved by membrane-associated serine proteases—including PRSS22—near its N-terminus to release bioactive peptides that signal through formyl peptide receptors (FPR1, FPR2/ALX) (PMID:25362540, PMID:36414640). Through FPR2/ALX, ANXA1 suppresses platelet activation by blunting thrombin-induced Akt, calcium, Rap1 and αIIbβ3 integrin activation (PMID:31154815), drives Schwann cell proliferation and nerve regeneration via FPR2-AMPK (PMID:32856352), and promotes neutrophil-mediated resolution (PMID:33512489); via the FPR2-AMPK axis it also protects cardiomyocytes by enhancing fatty acid oxidation (PMID:39709478). ANXA1 additionally preserves vascular smooth muscle contractile phenotype through JunB/MYL9, guarding against aortic dissection (PMID:33757117). Intracellularly, ANXA1 acts as a protein-stability and signaling hub: it binds EphA2 to block Cbl-mediated ubiquitination and stabilize oncogenic EphA2 (PMID:32737118), sequesters PARP1 away from STAT3 to raise STAT3 activity and PD-L1 expression (PMID:37566399), binds Notch1 NICD to target it for degradation (PMID:39447086), binds GSK3β to inhibit its phosphorylation and block EMT (PMID:34002210), and promotes TBK1-IRF3-dependent IFN-β production against RNA viruses while reinforcing JAK1/STAT1 signaling (PMID:35604142). ANXA1 frequently converges on PI3K/AKT signaling to confer therapy resistance and survival across cancers (PMID:27172896, PMID:31882967, PMID:40126756). Its own abundance is controlled by ubiquitin-dependent turnover (FBXO32) (PMID:40126756), stabilization (RRM2) (PMID:34319001), and m6A-dependent translational regulation (METTL3/YTHDC1) (PMID:36269280, PMID:35974388), while SUMOylation-linked nuclear-to-cytoplasmic shifts govern its inflammatory output in microglia (PMID:37908731). A homozygous missense ANXA1 variant causes autosomal recessive parkinsonism and impairs microglial phagocytosis (PMID:34180078).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2003 High

    Established that ANXA1 is genetically required for glucocorticoid suppression of eicosanoid production and proliferation, moving it from correlate to obligate mediator of glucocorticoid action.

    Evidence Anx-A1 knockout fibroblast lines with COX-2/PLA2 expression and cell-cycle readouts under dexamethasone

    PMID:12553880

    Open questions at the time
    • Did not resolve how ANXA1 mechanistically inhibits PLA2
    • Receptor/effector mediating the externalized signal not defined here
  2. 2009 High

    Defined the upstream control of ANXA1 externalization, showing glucocorticoid-driven PKCα/β phosphorylation at Ser27 triggers membrane translocation and release, opposed by PP2A.

    Evidence Biochemistry, epifluorescence and EM in U937 cells with PKC activation, PP2A inhibition, thromboxane B2 assay

    PMID:19428336

    Open questions at the time
    • Mechanism of physical translocation across the membrane not defined
    • Identity of the externalization machinery unresolved
  3. 2014 Medium

    Identified the proteolytic event that converts full-length ANXA1 into a receptor-active peptide, linking externalization to FPR signaling and tumor invasion.

    Evidence Proteomic cleavage-site mapping (Ser28/Lys29) and invasion assays with MAPK/STAT3 inhibition in melanoma cells

    PMID:25362540

    Open questions at the time
    • Protease identity not established in this study
    • In vivo relevance of the peptide not tested
  4. 2016 High

    Showed ANXA1 drives PI3K/AKT-dependent therapy resistance downstream of ARID1A loss, establishing an oncogenic survival axis in HER2+ breast cancer.

    Evidence Genome-wide loss-of-function screen, shRNA, AKT-inhibitor rescue, two clinical cohorts

    PMID:27172896

    Open questions at the time
    • Direct molecular link from ANXA1 to AKT activation not defined
    • Whether secreted or intracellular ANXA1 mediates this is unclear
  5. 2016 Medium

    Extended ANXA1 immunoregulation to adaptive immunity and microRNA circuits, revealing reciprocal feedback loops controlling its own expression.

    Evidence T-cell GATA-3/FPR signaling assays and a miR-196a/ANXA1 3'UTR luciferase feedback loop in breast cancer cells

    PMID:27105503 PMID:27833268

    Open questions at the time
    • Direct vs indirect promoter regulation not fully resolved
    • In vivo contribution of the feedback loop limited
  6. 2019 High

    Demonstrated direct ANXA1 action on platelets via FPR2/ALX, defining its anti-thrombotic mechanism through suppression of Akt/calcium/Rap1 and integrin inside-out activation.

    Evidence AnxA1-/- mice, intravital microscopy, WRW4 antagonism, human platelet signaling assays in cerebral ischemia-reperfusion

    PMID:31154815

    Open questions at the time
    • Whether full-length or cleaved peptide is the active ligand on platelets not separated
    • Structural basis of FPR2 engagement unresolved
  7. 2020 High

    Revealed ANXA1 as an intracellular stability regulator, mapping its N-terminal binding to EphA2 and competition with Cbl that stabilizes oncogenic EphA2 signaling.

    Evidence Co-IP, competitive Cbl/ubiquitination assays, mutagenesis mapping, peptide disruption, in vivo tumor assays

    PMID:32737118

    Open questions at the time
    • Calcium-dependence of the EphA2 interaction not addressed
    • Generalizability beyond nasopharyngeal carcinoma untested here
  8. 2020 Medium

    Expanded ANXA1's FPR2-AMPK signaling role beyond inflammation to Schwann cell-driven nerve regeneration and endothelial angiogenesis.

    Evidence FPR2/AMPK knockdown, proliferation/migration assays, nerve crush model; FPR2/SHP2 axis in choroidal endothelium

    PMID:32856352 PMID:34595678

    Open questions at the time
    • Source and processing of ANXA1 ligand in these tissues not defined
    • Direct receptor binding not biochemically demonstrated
  9. 2021 High

    Established ANXA1 as a tissue-protective factor in vascular smooth muscle, defining the JunB/MYL9 contractile-phenotype pathway preventing aortic dissection.

    Evidence Global and VSMC-conditional Anxa1 knockouts, transcriptomics, Ac2-26 rescue, human AAD specimens

    PMID:33757117

    Open questions at the time
    • Receptor mediating intracellular vs extracellular ANXA1 effect not separated
    • Upstream trigger of phenotype switch unresolved
  10. 2021 Medium

    Linked ANXA1 to a Mendelian neurodegenerative disease, implicating it in microglial phagocytic clearance.

    Evidence Homozygosity mapping, whole-genome sequencing, zebrafish phagocytosis assay

    PMID:34180078

    Open questions at the time
    • Molecular mechanism connecting variant to phagocytosis defect not defined
    • Human neuronal/microglial validation absent
  11. 2021 Medium

    Identified post-translational control of ANXA1 abundance via RRM2-dependent stabilization driving AKT-dependent drug resistance.

    Evidence RRM2 enzymatic-dead mutant, protein stability and AKT assays, sunitinib resistance in vitro and in vivo

    PMID:34319001

    Open questions at the time
    • Mechanism by which RRM2 stabilizes ANXA1 not defined
    • Single-lab finding in renal carcinoma
  12. 2022 High

    Defined ANXA1 as a positive regulator of antiviral interferon, acting through TBK1-IRF3 and reinforcing JAK1/STAT1 signaling, and a target of viral antagonism.

    Evidence ANXA1-/- cells, Co-IP of TBK1/JAK1/STAT1, IFN-β assays, FMDV 3A interaction mapping

    PMID:35604142

    Open questions at the time
    • Whether ANXA1 directly activates TBK1 kinase activity not shown
    • Structural basis of complex formation undefined
  13. 2022 Medium

    Showed ANXA1 binds GSK3β to suppress EMT and identified the protease PRSS22 that cleaves ANXA1 to drive FPR2/ERK metastatic signaling, expanding both intracellular and extracellular tumor mechanisms.

    Evidence GST pulldown/Co-IP with GSK3β functional rescue; MS/Co-IP and cleavage assays for PRSS22 with E2F1 ChIP

    PMID:34002210 PMID:36414640

    Open questions at the time
    • Reconciliation of ANXA1's opposing pro- and anti-tumor roles unresolved
    • Direct enzymatic kinetics of PRSS22 cleavage not quantified
  14. 2023 High

    Revealed an ANXA1-PARP1-STAT3 axis controlling immune evasion, defining ANXA1 as a PARP1 sponge that elevates STAT3 activity and PD-L1.

    Evidence Co-IP of ANXA1-PARP1 and PARP1-STAT3, STAT3 PARylation/phosphorylation assays, PD-L1 and T-cell killing, in vivo immunocompetent tumor model

    PMID:37566399

    Open questions at the time
    • Stoichiometry of sequestration not defined
    • Whether nuclear ANXA1 mediates this not directly shown
  15. 2023 High

    Demonstrated SUMOylation-coupled nuclear-to-cytoplasmic relocalization of ANXA1 controls NF-κB-driven microglial neuroinflammation through NBR1-dependent IKKα autophagy.

    Evidence Confocal localization, Co-IP, NF-κB reporter, conditional AAV manipulation in Cx3cr1-Cre mice, MCAO stroke model

    PMID:37908731

    Open questions at the time
    • SUMO sites on ANXA1 not mapped
    • Trigger of nuclear-cytoplasmic shift in physiological injury unresolved
  16. 2025 Medium

    Identified FBXO32 as the E3 ligase that ubiquitinates ANXA1 for degradation, completing a picture of bidirectional control of ANXA1 protein levels.

    Evidence Co-IP, ubiquitination assay, FBXO32 knockdown, ANXA1-rescue with PI3K/AKT readout in LPS cardiac injury models

    PMID:40126756

    Open questions at the time
    • Degron on ANXA1 not mapped
    • Signal regulating FBXO32-ANXA1 engagement unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ANXA1's opposing roles—anti-inflammatory resolution agent versus context-dependent oncogenic survival/immunosuppressive factor—are determined by localization, processing, and receptor usage remains unresolved.
  • No unified framework distinguishing intracellular vs externalized/cleaved functions
  • Structural basis of FPR1 vs FPR2 selectivity undefined
  • In vivo physiological control of nuclear vs cytoplasmic ANXA1 incompletely mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 4 GO:0098772 molecular function regulator activity 4 GO:0060090 molecular adaptor activity 2 GO:0008289 lipid binding 1
Localization
GO:0005576 extracellular region 3 GO:0005886 plasma membrane 2 GO:0005634 nucleus 1 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-168256 Immune System 4 R-HSA-392499 Metabolism of proteins 3 R-HSA-8953897 Cellular responses to stimuli 3
Partners
EPHA2FBXO32GSK3BJAK1NOTCH1PARP1RRM2TBK1

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Anx-A1 is required for glucocorticoid-mediated inhibition of eicosanoid generation and cell proliferation; Anx-A1-/- lung fibroblasts overexpress COX-2, cytosolic PLA2, and secretory PLA2, and are refractory to dexamethasone inhibition of serum-induced progression from G0/G1 to S phase, despite normal glucocorticoid receptor expression. Anx-A1(-/-) mouse-derived cell lines; comparative biochemical analysis of COX-2, PLA2 expression; cell cycle analysis; dexamethasone treatment with/without glucocorticoid receptor assessment The Biochemical journal High 12553880
2009 Glucocorticoids activate PKCα/β, which phosphorylates ANXA1 on Ser27, driving its accumulation at the plasma membrane and subsequent externalization, thereby inhibiting thromboxane B2 generation; cromoglycate drugs enhance this pathway by inhibiting the PP2A phosphatase that otherwise limits ANXA1 release. Biochemical assays, epifluorescence and electron microscopy in U937 cells; PKC activation assay; PP2A inhibition; thromboxane B2 measurement by RIA Biochemical pharmacology High 19428336
2014 In melanoma cells, externalized full-length ANXA1 is cleaved by a membrane-associated serine protease at a site between Ser28 and Lys29, releasing a pro-invasive N-terminal peptide (ANXA1 2-28) that activates formyl peptide receptors; ANXA1-driven invasion is mediated through MAPK and STAT3 pathways and leads to MMP2 induction. Proteomic/biochemical characterization of cleavage site; cell invasion assays; pharmacological inhibition of MAPK and STAT3; conditioned medium experiments in melanoma cell lines Archives of dermatological research Medium 25362540
2016 ANXA1 loss-of-function activates ANXA1 expression downstream of ARID1A loss, and ANXA1 then activates AKT signaling to confer resistance to HER2/PI3K/mTOR-targeting drugs including trastuzumab in HER2+ breast cancer cells. Genome-wide loss-of-function genetic screen; shRNA knockdown; pharmacological rescue with AKT inhibitor MK2206; gene expression analysis; validated in two independent clinical cohorts Clinical cancer research High 27172896
2016 ANXA1 suppresses oncogenic miR-196a biogenesis by stimulating c-Myc and NF-κB expression in breast cancer cells; miR-196a reciprocally targets the ANXA1 3'UTR to directly inhibit ANXA1 expression, forming a negative feedback loop that regulates cell proliferation. miRNA biogenesis assays; c-Myc/NF-κB expression and activity measurements; luciferase reporter assay for miR-196a targeting of ANXA1; gain/loss-of-function cell proliferation assays; in vivo tumor growth Oncotarget Medium 27105503
2016 ANXA1 modulates Th1/Th2 differentiation in CD4+ T cells by regulating GATA-3 expression through the FPR (FPRL-1) downstream ERK and PKB/Akt signaling pathways; conversely, GATA-3 inhibits ANXA1 expression by binding to its promoter. ANXA1 overexpression and knockdown in T cells; cytokine measurements (IFN-γ, IL-4); western blot for GATA-3/T-bet; pharmacological pathway inhibition; chromatin binding assay for GATA-3 on ANXA1 promoter Mediators of inflammation Medium 27833268
2018 AnxA1 establishes an autocrine signaling loop in triple-negative breast cancer MDA-MB-231 cells via secreted ANXA1 binding to FPR1, which increases cell aggressiveness and survival; pharmacological inhibition of FPR1 (Cyclosporin H or Cyclosporin A) reduces tumor growth and metastasis in nude mice. FPR1 inhibitor treatment (Cyclosporin H, Cyclosporin A); ANXA1 secretion quantification; cell aggressiveness assays in vitro; in vivo tumor growth and metastasis in nude mice; tissue microarray correlation of ANXA1 and FPR1 Biochimica et biophysica acta. Molecular cell research Medium 29932988
2019 AnxA1 acts directly on platelets via FPR2/ALX, suppressing thrombin-induced Akt activation, intracellular calcium release, and Rap1 expression, thereby decreasing αIIbβ3 integrin activation (without altering surface expression) and reducing platelet aggregation and thrombus formation in cerebral ischemia-reperfusion injury. AnxA1-/- mice; intravital microscopy; pharmacological treatment with AnxA1 and FPR2/ALX antagonist WRW4; thromboxane B2 measurement; phosphatidylserine expression assay; Akt/calcium/Rap1 signaling assays in human platelets Circulation High 31154815
2019 ANXA1 upregulation in colorectal cancer cells in response to hydrodynamic stress promotes cancer cell cluster growth via downstream activation of the PI3K/AKT signaling pathway. Microarray analysis of stressed cancer tissue-originated spheroids (CTOS); ANXA1 knockdown; PI3K/AKT pathway inhibition; growth assays Scientific reports Medium 31882967
2020 ANXA1 binds directly to EphA2 (via amino acid residues 20–30 and 28–30 of its N-terminus) and competes with the E3 ubiquitin ligase Cbl, thereby inhibiting Cbl-mediated EphA2 ubiquitination and proteasomal degradation, stabilizing EphA2 and increasing its oncogenic pS897-EphA2 signaling in nasopharyngeal carcinoma. Co-immunoprecipitation; competitive binding assay with Cbl; ubiquitination assay; mutagenesis mapping of ANXA1 N-terminal binding residues; EphA2 stability assays; in vitro and in vivo tumor growth assays; ANXA1-derived peptide disruption experiments Cancer research High 32737118
2020 ANXA1 interaction with ANXA4 mediates JAK-STAT3 signaling activation in basal-like breast cancer: ANXA4 directly binds ANXA1 (co-IP confirmed), and ANXA1 knockdown reduces JAK1 expression and STAT3 phosphorylation (Y705), impairing ANXA4-induced JAK-STAT3 activation. Co-immunoprecipitation; ANXA1 knockdown; JAK1 expression and STAT3 phosphorylation western blot; colocalization by immunofluorescence; in vivo tumor model DNA and cell biology Medium 32552056
2020 ANXA1 directs Schwann cell proliferation and migration after peripheral nerve injury by activating formyl peptide receptor 2 (FPR2) and its downstream AMPK signaling cascade; Schwann cells lacking FPR2 or AMPK show defects in proliferation and migration, and ANXA1 promotes nerve regeneration in vivo. FPR2/AMPK knockdown in Schwann cells; proliferation and migration assays; facial nerve crush injury model; in vivo remyelination assessment FASEB journal Medium 32856352
2021 AnxA1Ac2-26 (ANXA1 mimetic peptide) regulates SCD neutrophils through the FPR2/ALX pathway, activating Akt and ERK1/2 to enable resolution of cerebral thromboinflammatory responses in sickle cell disease mice. Sickle transgenic mice; pharmacological administration of AnxA1Ac2-26; FPR2/ALX pathway modulation; Akt and ERK1/2 signaling analysis; intravital microscopy of cerebral thrombosis Blood Medium 33512489
2021 ANXA1 in vascular smooth muscle cells prevents acute aortic dissection by maintaining the contractile phenotype via the JunB/MYL9 pathway; ANXA1 deficiency triggers VSMC synthetic phenotype switch, elevating inflammation and MMP production leading to elastin degradation. Anxa1-/- global and VSMC-restricted conditional knockout mice; transcriptomic analysis; micro-CT; immunohistochemistry; Ac2-26 rescue experiment; validation in human AAD specimens Cardiovascular research High 33757117
2021 ANXA1 directly binds the intracellular domain of Notch1 (NICD) and targets it for degradation, suppressing Notch1-mediated p15 promoter activation and thereby promoting AML cell proliferation. Co-immunoprecipitation; NICD stability assays; luciferase reporter for p15 promoter; ANXA1 knockdown/overexpression; NICD inhibitory peptide; patient sample correlation analysis Advanced science Medium 39447086
2021 A novel homozygous missense variant in ANXA1 causes autosomal recessive parkinsonism; the variant impairs phagocytosis in zebrafish mutant embryos, linking ANXA1 to microglial clearance of aggregated proteins. Homozygosity mapping; whole genome sequencing; zebrafish morpholino/mutant phagocytosis assay Annals of neurology Medium 34180078
2022 FMDV viral protein 3A interacts with ANXA1 and inhibits ANXA1-TBK1 complex formation, thereby blocking ANXA1-promoted IFN-β production; endogenous ANXA1 promotes RNA virus-stimulated IFN-β production through the TBK1-IRF3 axis (not NF-κB), and ANXA1 also interacts with JAK1 and STAT1 to strengthen IFN-β/IFN-γ signal transduction. Co-immunoprecipitation; ANXA1-/- knockout cells; IFN-β production assays; IRF3 and NF-κB pathway dissection; ANXA1-3A interaction mapping; JAK1/STAT1 co-IP Journal of virology High 35604142
2022 ANXA1 interacts with GSK3β (confirmed by GST pulldown and Co-IP), negatively regulates GSK3β phosphorylation, and thereby inhibits EMT and suppresses migration and invasion of NSCLC cells. GST pulldown; co-immunoprecipitation in H1299 and A549 cells; GSK3β phosphorylation assay; functional rescue assay for EMT/migration/invasion Acta biochimica et biophysica Sinica Medium 34002210
2022 E2F1-transcribed serine protease PRSS22 physically interacts with ANXA1 (confirmed by mass spectrometry and Co-IP), cleaves ANXA1 to generate an N-terminal peptide that activates the FPR2/ERK signaling axis, promoting breast cancer cell invasion and metastasis. Protein mass spectrometry; co-immunoprecipitation; cleavage assay; FPR2/ERK signaling analysis; ChIP for E2F1 on PRSS22 promoter; in vitro and in vivo metastasis assays Cell death & disease Medium 36414640
2022 CYP2J2 upregulates METTL3, which promotes ANXA1 translation via m6A modification of ANXA1 mRNA; ANXA1 is required for maintenance of endothelial tight junction/adherens junction distribution and blood-retinal barrier integrity under oxidative stress. CYP2J2 overexpression; METTL3 knockdown; MeRIP-qPCR for m6A on ANXA1 mRNA; endothelial ANXA1 conditional deletion; tight junction fractionation; BRB integrity assay in ischemia-reperfusion model FASEB journal Medium 36269280
2023 ANXA1 acts as a sponge that sequesters PARP1, preventing PARP1 from binding and poly(ADP-ribosyl)ating Stat3; reduced PARP1-Stat3 interaction decreases Stat3 dephosphorylation and thereby increases Stat3 transcriptional activity, leading to upregulated PD-L1 expression and cancer immune evasion. Co-immunoprecipitation of ANXA1-PARP1 and PARP1-Stat3; ANXA1 knockdown; PARylation assay of Stat3; Stat3 phosphorylation/dephosphorylation analysis; PD-L1 expression; T cell killing assay; in vivo immune-competent mouse tumor model Cancer immunology research High 37566399
2023 An ANXA1-derived peptide A11 competes with deubiquitinase USP7 for binding PD-L1, preventing USP7-mediated PD-L1 deubiquitination and thereby promoting PD-L1 proteasomal degradation in breast, lung, and melanoma cancer cells. Biotin pull-down coupled with mass spectrometry; human deubiquitinase cDNA library screen to identify USP7; competitive binding assay (A11 vs USP7 for PD-L1); ubiquitination/deubiquitination assays; T cell killing assay; in vivo mouse tumor model with immune competent mice Journal for immunotherapy of cancer High 37001908
2023 Tat-NTS peptide shifts ANXA1 subcellular localization in microglia from the nucleus to the cytoplasm after ischemic injury; this shift increases ANXA1 SUMOylation, which mediates IKKα degradation via NBR1-dependent selective autophagy, blocking NF-κB pathway activation and reducing pro-inflammatory cytokine (IL-1β, TNF-α) production. Confocal imaging with 3D reconstruction; Co-IP; immunoblotting; ELISA; luciferase reporter assay for NF-κB; AAV-mediated Cre-conditional manipulation in Cx3cr1-Cre mice; MCAO stroke model; behavioral tests; TEM Theranostics High 37908731
2023 SBSN interacts with ANXA1, and this interaction promotes Lys63-linked and Met1-linear polyubiquitination of NEMO, activating NF-κB signaling to drive glioma cell aggressiveness. Co-immunoprecipitation of SBSN-ANXA1-NEMO; ubiquitin-linkage-specific assays; in vivo tumor assay; EV transfer experiments Oncogene Medium 36316443
2021 ANXA1 interacts with TNFR1 (confirmed by Co-IP) and promotes glioma cell growth by activating the p65 and Akt signaling pathways downstream of TNF-α stimulation. Co-immunoprecipitation; ANXA1 knockdown/overexpression; p65 and Akt pathway western blot; CCK-8 proliferation assay; immunofluorescence Open life sciences Low 35415239
2021 ANXA1 is required for KIAA1199-mediated extracellular hyaluronic acid degradation on the surface of rheumatoid arthritis fibroblast-like synoviocytes: the G8 domain of KIAA1199 binds ANXA1 on the cell membrane to anchor KIAA1199, and deletion of this domain abolishes HA-degrading activity in vivo. Co-IP of KIAA1199 G8 domain with ANXA1; G8-deleted KIAA1199 mutant intra-articular injection in kiaa1199-KO mice; HA degradation assays; CIA mouse model Cell death & disease Medium 33473125
2022 ANXA1 reduction in macrophages in a diabetic periodontitis environment is associated with activation of the NLRP3/Caspase-1/GSDMD signaling pathway and increased macrophage pyroptosis; the ANXA1 mimetic peptide Ac2-26 reduces macrophage pyroptosis via this pathway. Western blot for NLRP3/Caspase-1/GSDMD in diabetic periodontitis macrophages; Ac2-26 peptide treatment; in vivo diabetic rat periodontitis model; ROS/pH-responsive hydrogel delivery system Biofabrication Low 39773706
2017 In hepatopulmonary syndrome, endothelin-1 reduces ANXA1 protein levels through carbonylation and proteasomal degradation of ANXA1; ANXA1 in turn decreases nuclear pERK1/2 accumulation and cyclin D1 expression, inhibiting pulmonary artery smooth muscle cell proliferation. Carbonylation assay of ANXA1 protein; proteasome inhibitor rescue; pERK1/2 nuclear fractionation; cyclin D1 western blot; PASMC proliferation assay PloS one Medium 28414743
2015 ANXA1 overexpression induced by low-concentration arsenic trioxide activates ERK MAPK signaling, rendering cancer cells resistant to ATO; ANXA1 silencing combined with ATO increases apoptosis, and pharmacological ERK inhibition (PD98059) phenocopies ANXA1 silencing. siRNA knockdown of ANXA1; ERK inhibitor PD98059; MTT proliferation/apoptosis assay; western blot for ERK activation; proteomics screen identifying ANXA1 as ATO-responsive protein Tumori Medium 25983101
2021 ANXA1 enhances the immunosuppressive function of Tregs in triple-negative breast cancer and reduces the expression of granzyme A mRNA in Tregs, as assessed by suppressive assays and RNA sequencing; the ANXA1 blocker Boc1 reduces Treg function and tumor size in vivo. Suppressive assay of Tregs; RNA sequencing after Boc1 treatment; ELISA for plasma ANXA1; in vivo tumor model with Boc1 treatment in BALB/c mice Journal for immunotherapy of cancer Medium 32300050
2020 ANXA1 promotes Schwann cell proliferation and migration through FPR2-AMPK signaling, acting as an extracellular trigger; endothelial ANXA1 promotes choroidal endothelial cell proliferation, migration, and tube formation via FPR2/SHP2 axis-mediated inhibition of NLRP3 inflammasome and pyroptosis. (For choroidal angiogenesis) FPR2/SHP2 knockdown; NLRP3 inhibition; pyroptosis markers; ARPE-19 and HCEC co-culture; ANXA1 secretion under hypoxia; in vivo CNV model Inflammation Medium 34595678
2025 FBXO32 E3 ubiquitin ligase directly ubiquitinates ANXA1, promoting its proteasomal degradation; loss of ANXA1 inhibits PI3K/AKT signaling and exacerbates LPS-induced cardiac injury and apoptosis. Co-immunoprecipitation; ubiquitination assay; FBXO32 knockdown; ANXA1 knockdown rescue experiment; PI3K/AKT western blot; in vivo and in vitro LPS cardiac injury models Inflammation Medium 40126756
2020 WISP1 recruits ANXA1 as an interaction partner (identified by Co-IP and mass spectrometry) to regulate TGF-β signaling pathway during muscle-derived satellite cell differentiation; WISP1 cannot affect TGF-β signaling markers when ANXA1 is knocked down. Co-immunoprecipitation; mass spectrometry; ANXA1 knockdown with WISP1 activation; western blot for TGF-β pathway proteins; immunofluorescence Molecular and cellular biochemistry Low 32458119
2010 α-MSH inhibits TNF-α-induced maturation of human monocyte-derived dendritic cells through upregulation of ANXA1; specific siRNA knockdown of ANXA1 abolishes the α-MSH inhibitory effect on DC maturation markers (CD83, CD86), IL-12 production, and phagocytic activity. siRNA knockdown of ANXA1; flow cytometry for CD83/CD86; ELISA for IL-12/IL-10; phagocytosis assay; α-MSH treatment Acta biochimica et biophysica Sinica Medium 21131366
2013 FoxM1 transcription factor directly transcriptionally activates ANXA1 expression in glioma cells; overexpression of FoxM1 upregulates ANXA1, and FoxM1-driven proliferation, migration, and angiogenesis occur in an ANXA1-dependent manner. FoxM1 overexpression/knockdown; ChIP or promoter assay for FoxM1 on ANXA1; ANXA1 knockdown rescue; proliferation, migration, angiogenesis assays in vitro and in vivo PloS one Medium 23991102
2021 RRM2 stabilizes ANXA1 protein and activates the AKT pathway independent of its ribonucleotide reductase activity, promoting sunitinib resistance in renal cell carcinoma. RRM2 knockdown/overexpression; ANXA1 protein stability assays; AKT pathway western blot; sunitinib resistance assays in vitro and in vivo; RRM2 enzymatic-dead mutant Advanced science Medium 34319001
2024 The ANXA1-FPR2 axis protects against obesity-associated atrial fibrillation by activating AMPK in cardiomyocytes to enhance fatty acid oxidation and reduce lipid accumulation; AAV9-mediated AMPK knockdown in myocardium reverses the protective effect of Ac2-26 on AF susceptibility in obese mice. High-fat diet obese mice; AAV9-shAMPK myocardial-specific knockdown; FPR2 inhibitor (Boc-2, WRW4); Ac2-26 peptide administration; fatty acid oxidation assays; in vitro palmitic acid cardiomyocyte model Cardiovascular diabetology Medium 39709478
2024 CAM-A-induced nuclear aggregation of HBV core protein (HBc) upregulates ANXA1 expression, and ANXA1 directly mediates apoptosis in HBV-infected cells; ANXA1 silencing delays cell death and apoptosis in CAM-A-treated cells. siRNA knockdown of ANXA1 in HBV-infected differentiated HepaRG cells and HBc-overexpressing HepG2-NTCP cells; transcriptomic analysis; apoptosis markers; primary human hepatocytes JHEP reports Medium 39386256
2022 YTHDC1 (m6A reader) inhibits ANXA1 expression in ccRCC via RNA binding (RIP-qPCR/MeRIP-qPCR), and ANXA1 activates the MAPK pathway downstream; the YY1/HDAC2 epigenetic complex downregulates YTHDC1, which de-represses ANXA1/MAPK signaling and promotes sunitinib resistance. RIP-qPCR; MeRIP-qPCR; RNA-seq; western blot; HDAC2 inhibitor treatment; xenograft assay Journal of experimental & clinical cancer research Medium 35974388
2021 ANXA1 from intestinal epithelial cells (IECs) stimulates NKG2A expression on natural killer cells during colitis; NKG2A upregulation on NK cells inhibits neutrophil recruitment and activity, alleviating DSS-induced colitis. DSS colitis mouse model; ANXA1 overexpression in IECs; NK-IEC co-culture; NKG2A expression measurement; neutrophil infiltration assay Biochemical and biophysical research communications Low 27435504
2023 ANXA1 drives glioma immunosuppression via FPR1 signaling: tumor-derived ANXA1 induces M2-like macrophage/microglia polarization through FPR1, establishing a Treg-driven immunosuppressive tumor microenvironment and suppressing the anti-tumor immune response to TLR3 ligand poly(I:C). In vitro macrophage/microglia polarization assays; FPR1 pharmacological inhibition; in vivo glioma model; clinical trial patient sample analysis (RNA-seq and protein validation) Cellular & molecular immunology Medium 38049523

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet (London, England) 160 15183626
2021 RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 139 34319001
2019 Novel Role for the AnxA1-Fpr2/ALX Signaling Axis as a Key Regulator of Platelet Function to Promote Resolution of Inflammation. Circulation 126 31154815
2020 Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer. Journal for immunotherapy of cancer 89 32300050
2023 Tat-NTS peptide protects neurons against cerebral ischemia-reperfusion injury via ANXA1 SUMOylation in microglia. Theranostics 67 37908731
2021 Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease. Blood 64 33512489
2022 YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway. Journal of experimental & clinical cancer research : CR 61 35974388
2023 ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers. Cancer immunology research 55 37566399
2022 Anxa1 in smooth muscle cells protects against acute aortic dissection. Cardiovascular research 55 33757117
2016 ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-kB and c-Myc to reduce breast cancer proliferation. Oncotarget 54 27105503
2016 Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 54 27172896
2003 Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. The Biochemical journal 54 12553880
2018 Inhibition of the AnxA1/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo. Biochimica et biophysica acta. Molecular cell research 53 29932988
2020 The crosstalk of ABCA1 and ANXA1: a potential mechanism for protection against atherosclerosis. Molecular medicine (Cambridge, Mass.) 51 32894039
2020 ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis. Cancer research 50 32737118
2020 DCST1-AS1 Promotes TGF-β-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1. Frontiers in oncology 47 32226772
2014 Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers. BMC cancer 47 25038797
2016 Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness. Cell adhesion & migration 45 27834582
2023 ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. Journal for immunotherapy of cancer 42 37001908
2023 Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment. Cellular & molecular immunology 38 38049523
2016 Interaction between ANXA1 and GATA-3 in Immunosuppression of CD4+ T Cells. Mediators of inflammation 36 27833268
2021 Secreted KIAA1199 promotes the progression of rheumatoid arthritis by mediating hyaluronic acid degradation in an ANXA1-dependent manner. Cell death & disease 35 33473125
2017 Evaluation of miRNA-196a2 and apoptosis-related target genes: ANXA1, DFFA and PDCD4 expression in gastrointestinal cancer patients: A pilot study. PloS one 35 29091952
2022 SPP1/AnxA1/TIMP1 as Essential Genes Regulate the Inflammatory Response in the Acute Phase of Cerebral Ischemia-Reperfusion in Rats. Journal of inflammation research 33 36046663
2021 ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma. Journal of Cancer 33 33531975
2020 Targeting AnxA1/Formyl Peptide Receptor 2 Pathway Affords Protection against Pathological Thrombo-Inflammation. Cells 31 33202930
2013 FoxM1 promotes glioma cells progression by up-regulating Anxa1 expression. PloS one 31 23991102
2001 An annexin 1 (ANXA1)-derived peptide inhibits prototype antigen-driven human T cell Th1 and Th2 responses in vitro. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 31 11468004
2016 Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro. Molecular medicine reports 30 27035116
2019 Antioxidant activity changes of exopolysaccharides with different carbon sources from Lactobacillus plantarum LPC-1 and its metabolomic analysis. World journal of microbiology & biotechnology 29 31011829
2009 Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. Biochemical pharmacology 29 19428336
2017 ANXA1 affects cell proliferation, invasion and epithelial-mesenchymal transition of oral squamous cell carcinoma. Experimental and therapeutic medicine 28 29201239
2014 Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer. International journal of clinical and experimental pathology 28 25337195
2014 Characterization of pro-invasive mechanisms and N-terminal cleavage of ANXA1 in melanoma. Archives of dermatological research 28 25362540
2020 ANXA1 directs Schwann cells proliferation and migration to accelerate nerve regeneration through the FPR2/AMPK pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 26 32856352
2015 Proteomic Characterization of Annexin l (ANX1) and Heat Shock Protein 27 (HSP27) as Biomarkers for Invasive Hepatocellular Carcinoma Cells. PloS one 26 26431426
2019 Hydrodynamic stress stimulates growth of cell clusters via the ANXA1/PI3K/AKT axis in colorectal cancer. Scientific reports 24 31882967
2010 Differential roles of Annexin A1 (ANXA1/lipocortin-1/lipomodulin) and thioredoxin binding protein-2 (TBP-2/VDUP1/TXNIP) in glucocorticoid signaling of HTLV-I-transformed T cells. Immunology letters 22 20398702
2022 E2F1-initiated transcription of PRSS22 promotes breast cancer metastasis by cleaving ANXA1 and activating FPR2/ERK signaling pathway. Cell death & disease 21 36414640
2021 Exosomal ANXA1 derived from thyroid cancer cells is associated with malignant transformation of human thyroid follicular epithelial cells by promoting cell proliferation. International journal of oncology 21 34779491
2019 The GR-ANXA1 pathway is a pathological player and a candidate target in epilepsy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21 31618599
2020 ANXA1‑derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation. International journal of oncology 20 32901832
2025 M2 Macrophage-Derived Extracellular Vesicles Reprogram Immature Neutrophils into Anxa1hi Neutrophils to Enhance Inflamed Bone Regeneration. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 19 40277454
2021 Crosstalk Between RPE Cells and Choroidal Endothelial Cells via the ANXA1/FPR2/SHP2/NLRP3 Inflammasome/Pyroptosis Axis Promotes Choroidal Neovascularization. Inflammation 19 34595678
2014 Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 19 24453033
2020 Immunoproteomics approach revealed elevated autoantibody levels against ANXA1 in early stage gallbladder carcinoma. BMC cancer 18 33261560
2018 Endogenous annexin A1 (AnxA1) modulates early-phase gestation and offspring sex-ratio skewing. Journal of cellular physiology 18 29115663
2013 Overexpression of ANXA1 in penile carcinomas positive for high-risk HPVs. PloS one 18 23341933
2022 Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated ANXA1 upregulation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17 36269280
2021 Cytotoxicity and growth-inhibiting activity of Astragalus polysaccharides against breast cancer via the regulation of EGFR and ANXA1. Journal of natural medicines 17 34043154
2024 Mitigation of acute lung injury by human bronchial epithelial cell-derived extracellular vesicles via ANXA1-mediated FPR signaling. Communications biology 16 38710749
2019 RETRACTED: Up-regulation of ANXA1 suppresses polymorphonuclear neutrophil infiltration and myeloperoxidase activity by activating STAT3 signaling pathway in rat models of myocardial ischemia-reperfusion injury. Cellular signalling 15 31132398
2015 ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. Tumori 15 25983101
2022 Methylprednisolone up-regulates annexin A1 (ANXA1) to inhibit the inflammation, apoptosis and oxidative stress of cigarette smoke extract (CSE)-induced bronchial epithelial cells, a chronic obstructive pulmonary disease in vitro model, through the formyl peptide receptor 2 (FPR2) receptors and the adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) pathway. Bioengineered 14 35129068
2021 New insight into the role of ANXA1 in melanoma progression: involvement of stromal expression in dissemination. American journal of cancer research 14 33948376
2019 miR-196a regulates the proliferation, invasion and migration of esophageal squamous carcinoma cells by targeting ANXA1. Oncology letters 14 31186736
2022 FMDV 3A Antagonizes the Effect of ANXA1 to Positively Modulate Viral Replication. Journal of virology 13 35604142
2020 ANXA4 Activates JAK-STAT3 Signaling by Interacting with ANXA1 in Basal-Like Breast Cancer. DNA and cell biology 13 32552056
2017 ANXA1Ac2-26 peptide, a possible therapeutic approach in inflammatory ocular diseases. Gene 13 28257834
2014 Investigation of circulating antibodies to ANXA1 in breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 13 25344217
2016 Skin Wound Repair Is Not Altered in the Absence of Endogenous AnxA1 or AnxA5, but Pharmacological Concentrations of AnxA4 and AnxA5 Inhibit Wound Hemostasis. Cells, tissues, organs 12 27178140
2015 Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1. Molecular and cellular biochemistry 12 26369530
2023 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis. Oncogene 11 36732658
2023 Mucosal expression of PI3, ANXA1, and VDR discriminates Crohn's disease from ulcerative colitis. Scientific reports 11 37891214
2021 ANXA1 with Anti-Inflammatory Properties Might Contribute to Parkinsonism. Annals of neurology 11 34180078
2025 Ameliorating macrophage pyroptosis via ANXA1/NLRP3/Caspase-1/GSDMD pathway: Ac2-26/OGP-loaded intelligent hydrogel enhances bone healing in diabetic periodontitis. Biofabrication 10 39773706
2024 ECM1 and ANXA1 in urinary extracellular vesicles serve as biomarkers for breast cancer. Frontiers in oncology 10 39040439
2024 ANXA1-FPR2 axis mitigates the susceptibility to atrial fibrillation in obesity via rescuing AMPK activity in response to lipid overload. Cardiovascular diabetology 10 39709478
2022 Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-κB via ANXA1-dependent ubiquitination of NEMO. Oncogene 10 36316443
2021 Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients. Frontiers in cell and developmental biology 10 34912807
2016 The ANXA1 released from intestinal epithelial cells alleviate DSS-induced colitis by improving NKG2A expression of Natural Killer cells. Biochemical and biophysical research communications 10 27435504
1979 Studies with murine LPC-1 plasmacytoma using [6-14C]arginine. Cell and tissue kinetics 10 84712
2024 Qingxin Jieyu Granule alleviates myocardial infarction through inhibiting neutrophil extracellular traps via activating ANXA1/FPR2 axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 9 39418972
2023 JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer. Molecular cancer research : MCR 9 36867680
2021 ANXA1-GSK3β interaction and its involvement in NSCLC metastasis. Acta biochimica et biophysica Sinica 9 34002210
2021 ANXA1 (Annexin A1) regulated by MYC (MYC proto-oncogene) promotes the growth of papillary thyroid carcinoma. Bioengineered 9 34723715
2021 The Pyrazolyl-Urea Gege3 Inhibits the Activity of ANXA1 in the Angiogenesis Induced by the Pancreatic Cancer Derived EVs. Biomolecules 9 34944403
2017 Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer. Anticancer research 9 28551657
2017 Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients. Journal of Cancer 9 29187872
2014 Recurrent duplications of the annexin A1 gene (ANXA1) in autism spectrum disorders. Molecular autism 9 24720851
2010 [Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 9 21122411
2005 Macrophage biology in the Anx-A1-/- mouse. Prostaglandins, leukotrienes, and essential fatty acids 9 15626592
2024 MiR-374a/b-5p Suppresses Cell Growth in Papillary Thyroid Carcinoma Through Blocking Exosomal ANXA1-Induced Macrophage M2 Polarization. Biochemical genetics 8 38536567
2023 ANXA1 is identified as a key gene associated with high risk and T cell infiltration in primary sclerosing cholangitis. Human genomics 8 37735492
2022 [Evaluation of Annexin-1 (ANXA-1), Annexin-2 (ANXA-2) and Bone Morphogenetic Protein-7 (BMP-7) Serum Levels in Patients Followed Up With A Diagnosis of COVID-19]. Mikrobiyoloji bulteni 8 35088957
2022 Potential regulatory mechanism of TNF-α/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation. Open life sciences 8 35415239
2017 The ET-1-mediated carbonylation and degradation of ANXA1 induce inflammatory phenotype and proliferation of pulmonary artery smooth muscle cells in HPS. PloS one 8 28414743
1979 Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer. Cancer research 8 445451
2025 Potential Crosstalk Between ANXA1+ Epithelial Cells and FABP4+ TAM Cells of Ferroptosis-Related Molecular Clusters Promotes an Immunosuppressive Microenvironment in Non-Small Cell Lung Cancer. Molecular carcinogenesis 7 40040274
2025 E3 Ubiquitin Ligase FBXO32 Promotes LPS-Induced Cardiac Injury by Regulating ANXA1/PI3K/AKT Signaling. Inflammation 7 40126756
2023 Deletion of Annexin A1 in Mice Upregulates the Expression of Its Receptor, Fpr2/3, and Reactivity to the AnxA1 Mimetic Peptide in Platelets. International journal of molecular sciences 7 36834844
2021 Expression and Functional Relevance of ANXA1 in Hypopharyngeal Carcinoma with Lymph Node Metastasis. OncoTargets and therapy 7 33658802
2020 WISP1 promotes bovine MDSC differentiation via recruitment of ANXA1 for the regulation of the TGF-β signalling pathway. Molecular and cellular biochemistry 7 32458119
2020 Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer. Journal of clinical medicine 7 33276477
2015 The Role and Effects of ANXA1 in Temporal Lobe Epilepsy: A Protection Mechanism? Medical science monitor basic research 7 26609771
2010 α-MSH inhibits TNF-α-induced maturation of human dendritic cells in vitro through the up-regulation of ANXA1. Acta biochimica et biophysica Sinica 7 21131366
2024 CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1. JHEP reports : innovation in hepatology 6 39386256
2024 Identification of ANXA1 as a Novel Upstream Negative Regulator of Notch1 Function in AML. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 6 39447086
2022 ANXA1 and the risk for early-onset Parkinson's disease. Neurobiology of aging 6 35240489
2018 MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer. Oncology letters 6 29552220

Missed literature

Know a paper Affinage missed for ANXA1? Flag it for the maintainers and the community.

No submissions yet.